{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:12:03Z","timestamp":1788261123312,"version":"build-2803163510"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Psilocybin may help treat obsessive\u2013compulsive disorder (OCD). To date, only one open-label study of psilocybin for OCD exists, necessitating further investigation with a randomized controlled design. The neural correlates of psilocybin\u2019s effects on OCD have also not been studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This first-of-its-kind trial aims to evaluate the feasibility, safety, and tolerability of psilocybin in the treatment of OCD, provide preliminary evidence on the effects of psilocybin on OCD symptoms, and elucidate neural mechanisms that may mediate psilocybin\u2019s effects on OCD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>We use a randomized (1:1), double-blind, placebo-controlled, non-crossover design to examine the clinical and neural effects of either a single dose of oral psilocybin (0.25\u2009mg\/kg) or active placebo-control agent (250\u2009mg of niacin) on OCD symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>We are enrolling 30 adult participants at a single site in Connecticut, USA who have failed at least one trial of standard care treatment (medication\/psychotherapy) for OCD. All participants will also receive unstructured, non-directive psychological support during visits. Aside from safety, primary outcomes include OCD symptoms over the past 24\u2009h, assessed by the Acute Yale-Brown Obsessive\u2013Compulsive Scale and Visual Analog Scale ratings. These are collected by blinded, independent raters at baseline and the primary endpoint of 48\u2009h post-dosing. Total follow-up is 12\u2009weeks post-dosing. Resting state neuroimaging data will be collected at baseline and primary endpoint. Participants randomized to placebo will be offered the chance to return for an open-label dose of 0.25\u2009mg\/kg.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics statement<\/jats:title><jats:p>All participants will be required to provide written informed consent. The trial (protocol v. 5.2) was approved by the institutional review board (HIC #2000020355) and registered with <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> (NCT03356483).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study may represent an advance in our ability to treat refractory OCD, and pave the way for future studies of neurobiological mechanisms of OCD that may respond to psilocybin.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1178529","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T04:42:45Z","timestamp":1682397765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive\u2013compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Terence H. W.","family":"Ching","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Grazioplene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Bohner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Kichuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"DePalmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Eilbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Jankovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Hokanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Witherow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerana","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Schaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pittenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kelmendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/S1092852912000697","article-title":"Quality of life in obsessive compulsive disorder","volume":"18","author":"Macy","year":"2013","journal-title":"CNS Spectr"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40263-013-0056-z","article-title":"Quality of life in obsessive-compulsive disorder: impact of the disorder and of treatment","volume":"27","author":"Subramaniam","year":"2013","journal-title":"CNS Drugs"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"114567","DOI":"10.1016\/j.psychres.2022.114567","article-title":"Latency to treatment seeking in patients with obsessive-compulsive disorder: results from a large multicenter clinical sample","volume":"312","author":"Costa","year":"2022","journal-title":"Psychiatry Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"CD001765","DOI":"10.1002\/14651858.CD001765.pub3","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)","volume":"2008","author":"Soomro","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.4088\/JCP.14r09758","article-title":"Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis","volume":"77","author":"Issari","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0004867412461958","article-title":"Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond","volume":"47","author":"Fineberg","year":"2013","journal-title":"Aust N Z J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1017\/S1461145702002900","article-title":"Treatment non-response in OCD: methodological issues and operational definitions","volume":"5","author":"Pallanti","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11920-012-0268-9","article-title":"A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder","volume":"14","author":"Stein","year":"2012","journal-title":"Curr Psychiatry Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/da.22728","article-title":"Cognitive behavioral therapy for anxiety and related disorders: a meta-analysis of randomized placebo-controlled trials","volume":"35","author":"Carpenter","year":"2018","journal-title":"Depress Anxiety"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/wps.20038","article-title":"The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons","volume":"12","author":"Cuijpers","year":"2013","journal-title":"World Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cpr.2015.06.003","article-title":"Cognitive behavioral treatments of obsessive-compulsive disorder. A systematic review and meta-analysis of studies published 1993-2014","volume":"40","author":"\u00d6st","year":"2015","journal-title":"Clin Psychol Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"152223","DOI":"10.1016\/j.comppsych.2021.152223","article-title":"Cognitive behavioural therapy with exposure and response prevention in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of randomised controlled trials","volume":"106","author":"Reid","year":"2021","journal-title":"Compr Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"100498","DOI":"10.1016\/j.jocrd.2019.100498","article-title":"Clinician-reported barriers to using exposure with response prevention in the treatment of paediatric obsessive-compulsive disorder","volume":"24","author":"Keleher","year":"2020","journal-title":"J Obsessive Compuls Relat Disord"},{"key":"ref16","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am J Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/da.20694","article-title":"Barriers to treatment and service utilization in an internet sample of individuals with obsessive-compulsive symptoms","volume":"27","author":"Marques","year":"2010","journal-title":"Depress Anxiety"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.psychres.2015.02.004","article-title":"Efficacy of cognitive-behavioral therapy for obsessive-compulsive disorder","volume":"227","author":"McKay","year":"2015","journal-title":"Psychiatry Res"},{"key":"ref19","first-page":"703","article-title":"Obsessive-compulsive disorder in ethnoracial minorities: symptoms, barriers to, and considerations for treatment","volume-title":"Obsessive-compulsive disorder: Phenomenology, pathophysiology, and treatment","author":"Williams","year":"2017"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/da.22103","article-title":"Long-term outcome in adults with obsessive-compulsive disorder","volume":"30","author":"Bloch","year":"2013","journal-title":"Depress Anxiety"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/YIC.0b013e3283613e4d","article-title":"Longitudinal course of pharmacotherapy in obsessive-compulsive disorder","volume":"28","author":"Grant","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"102407","DOI":"10.1016\/j.janxdis.2021.102407","article-title":"A meta-analysis of relapse rates in cognitive-behavioral therapy for anxiety disorders","volume":"81","author":"Levy","year":"2021","journal-title":"J Anxiety Disord"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2021-328738","article-title":"Efficacy of deep brain stimulation for treatment-resistant obsessive-compulsive disorder: systematic review and meta-analysis","volume":"93","author":"Gadot","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852922000888","article-title":"Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy","author":"Dodd","year":"2022","journal-title":"CNS Spectrums"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40263-021-00877-y","article-title":"Molecular mechanisms of psilocybin and implications for the treatment of depression","volume":"36","author":"Ling","year":"2022","journal-title":"CNS Drugs"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J Psychopharmacol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J Psychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14740338.2022.2047929","article-title":"The therapeutic potential of psilocybin: a systematic review","volume":"21","author":"van Amsterdam","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1239b","DOI":"10.1176\/ajp.144.9.1239b","article-title":"Relief of obsessive-compulsive symptoms by LSD and psilocin","volume":"144","author":"Leonard","year":"1987","journal-title":"Am J Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1037b","DOI":"10.1176\/ajp.154.7.1037b","article-title":"Hallucinogen-induced relief of obsessions and compulsions","volume":"154","author":"Moreno","year":"1997","journal-title":"Am J Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/02791072.2014.963754","article-title":"Psilocybin and obsessive-compulsive disorder","volume":"46","author":"Wilcox","year":"2014","journal-title":"J Psychoactive Drugs"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"","journal-title":"Arch Gen Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","article-title":"The Yale-Brown obsessive compulsive scale II Validity","volume":"46","author":"Goodman","year":"","journal-title":"Arch Gen Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1192\/bjp.bp.111.103309","article-title":"Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin","volume":"200","author":"Carhart-Harris","year":"2012","journal-title":"Br J Psychiatry"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","article-title":"Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning","volume":"228","author":"Catlow","year":"2013","journal-title":"Exp Brain Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1001\/jamapsychiatry.2013.914","article-title":"Deficits in conditioned fear extinction in obsessive-compulsive disorder and neurobiological changes in the fear circuit","volume":"70","author":"Milad","year":"2013","journal-title":"JAMA Psychiat"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin\u2013summary of knowledge and new perspectives","volume":"24","author":"Tyl\u0161","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1007\/s00213-021-05915-7","article-title":"Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder","volume":"239","author":"Martens","year":"2022","journal-title":"Psychopharmacol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.biopsych.2013.09.002","article-title":"The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder","volume":"75","author":"Shin","year":"2014","journal-title":"Biol Psychiatry"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiat"},{"key":"ref46","article-title":"Optimal design software for multi-level and longitudinal research","author":"Raudenbush","year":"2011"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuroimage.2019.04.009","article-title":"Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects","volume":"196","author":"Smigielski","year":"2019","journal-title":"NeuroImage"},{"key":"ref48","first-page":"22","article-title":"The Mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"ref49","volume-title":"SCID-II personality questionnaire","author":"First","year":"1997"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.31234\/osf.io\/85s9p","article-title":"Yale program for psychedelic science (YPPS) manual for psilocybin-OCD session monitors for protocol HIC: 2000020355","author":"Ching","year":"2022","journal-title":"PsyArxiv"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biol Psychiatry"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref54","volume-title":"Columbia-suicide severity rating scale (C-SSRS)","author":"Posner","year":"2008"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1037\/1040-3590.14.4.485","article-title":"The obsessive-compulsive inventory: development and validation of a short version","volume":"14","author":"Foa","year":"2002","journal-title":"Psychol Assess"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.brat.2008.04.002","article-title":"Incompleteness and harm avoidance in OCD symptom dimensions","volume":"46","author":"Ecker","year":"2008","journal-title":"Behav Res Ther"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0005-7967(88)90116-7","article-title":"Obsessions and compulsions: the Padua inventory","volume":"26","author":"Sanavio","year":"1988","journal-title":"Behav Res Ther"},{"key":"ref58","volume-title":"Manual for the state-trait anxiety inventory","author":"Spielberger","year":"1983"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"ref60","volume-title":"Beck depression inventory\u2013II (BDI-II)","author":"Beck","year":"1996"},{"key":"ref61","volume-title":"AUDIT: The alcohol use disorders identification test: Guidelines for use in primary care","author":"Babor","year":"2001"},{"key":"ref62","volume-title":"WHO collaborative project on the identification and treatment of persons with harmful alcohol consumption: Report on phase I, the development of a screening instrument","author":"Saunders","year":"1987"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000081413","article-title":"Evaluation of the drug use disorders identification test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample","volume":"11","author":"Berman","year":"2005","journal-title":"Eur Addict Res"},{"key":"ref64","volume-title":"Self-reported nicotine use (SRNU)","year":"2017"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.brat.2004.07.010","article-title":"Psychometric validation of the obsessive beliefs questionnaire and the interpretation of intrusions inventory: part 2: factor analyses and testing of a brief version","volume":"43","year":"2005","journal-title":"Behav Res Ther"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0887-6185(96)00018-7","article-title":"Thought-action fusion in obsessive compulsive disorder","volume":"10","author":"Shafran","year":"1996","journal-title":"J Anxiety Disord"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0005-7967(99)00071-6","article-title":"Responsibility attitudes and interpretations are characteristic of obsessive-compulsive disorder","volume":"38","author":"Salkovskis","year":"2000","journal-title":"Behav Res Ther"},{"key":"ref68","volume-title":"Big five aspects scale (BFAS)","author":"DeYoung","year":"2007"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2850.2011.01735.x","article-title":"Quality of life enjoyment and satisfaction questionnaire-short form for quality of life assessments in clinical practice: a psychometric study","volume":"18","author":"Stevanovic","year":"2011","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"ref70","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"ref71","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"ref73","volume-title":"The PANAS-X: Manual for the positive and negative affect schedule-expanded form","author":"Watson","year":"1994"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","article-title":"Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin","volume":"51","author":"MacLean","year":"2012","journal-title":"J Sci Study Relig"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref76","volume-title":"A short introduction","author":"Dittrich","year":"2010"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/0013916508318748","article-title":"The nature relatedness scale: linking individuals' connection with nature to environmental concern and behavior","volume":"41","author":"Nisbet","year":"2009","journal-title":"Environ Behav"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10745-013-9614-8","article-title":"Pro-environmental behavior: does it matter how it\u2019s measured? Development and validation of the pro-environmental behavior scale (PEBS)","volume":"41","author":"Markle","year":"2013","journal-title":"Hum Ecol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1745691610369336","article-title":"Who sees human? The stability and importance of individual differences in anthropomorphism","volume":"5","author":"Waytz","year":"2010","journal-title":"Perspect Psychol Sci"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1162\/jocn_a_00407","article-title":"Look again: effects of brain images and mind-brain dualism on lay evaluations of research","volume":"25","author":"Hook","year":"2013","journal-title":"J Cogn Neurosci"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1037\/0022-3514.63.4.596","article-title":"Inclusion of other in the self scale and the structure of interpersonal closeness","volume":"63","author":"Aron","year":"1992","journal-title":"J Pers Soc Psychol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1037\/0022-3514.39.1.175","article-title":"A taxonomy of ethical ideologies","volume":"39","author":"Forsyth","year":"1980","journal-title":"J Pers Soc Psychol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1037\/0022-3514.67.6.1063","article-title":"Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the life orientation test","volume":"67","author":"Scheier","year":"1994","journal-title":"J Pers Soc Psychol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jpainsymman.2007.05.007","article-title":"The schedule for meaning in life evaluation (SMiLE): validation of a new instrument for meaning-in-life research","volume":"35","author":"Fegg","year":"2008","journal-title":"J Pain Symptom Manag"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1037\/0022-3514.57.4.660","article-title":"Levels of personal agency: individual variation in action identification","volume":"57","author":"Vallacher","year":"1989","journal-title":"J Pers Soc Psychol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/08989620108573983","article-title":"Empirically supported ethical research practice: the costs and benefits of research from the participants' view","volume":"8","author":"Newman","year":"2001","journal-title":"Account Res"},{"key":"ref89","volume-title":"Reactions to research participation questionnaire","author":"Newman","year":"1996"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0899-3289(05)80057-4","article-title":"Stages of change profiles in alcoholism treatment","volume":"2","author":"DiClemente","year":"1990","journal-title":"J Subst Abus"},{"key":"ref91","volume-title":"Utilization of facility and emergent care (UFEC)","year":"2017"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1101\/2022.06.03.494750","article-title":"QuNex\u2013an integrative platform for reproducible neuroimaging analytics","author":"Ji","year":"2022","journal-title":"bioRxiv"},{"key":"ref93","volume-title":"Interpretative phenomenological analysis: theory, research, practice","author":"Smith","year":"2009"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1088896","DOI":"10.3389\/fpsyt.2023.1088896","article-title":"Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study","volume":"14","author":"Kaup","year":"2023","journal-title":"Front Psych"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1178529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T04:42:59Z","timestamp":1682397779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1178529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":94,"alternative-id":["10.3389\/fpsyt.2023.1178529"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1178529","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"article-number":"1178529"}}